BPC-157 and Crohn's disease: separating hope from hype

What's this video probably claiming?

Kevin Compere's video sits at the intersection of invisible illness advocacy and peptide therapy enthusiasm. The hashtags point to ulcerative colitis (RCH is rectocolite hémorragique, the French term) and Crohn's disease, and the emotional framing suggests a personal recovery story. Given the video is categorized under peptide therapy, the likely narrative is that something like BPC-157, TB-500, or a related peptide contributed meaningfully to managing inflammatory bowel disease (IBD) symptoms that conventional medicine failed to resolve. These testimonial-format videos are enormously effective at driving peptide interest among IBD communities specifically because the patient populations are younger, highly engaged online, and often frustrated with immunosuppressant side effects. That frustration is legitimate. The leap to peptides as the answer is not yet supported by human evidence.

What does the science actually show?

BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a protein found in gastric juice. The animal data is genuinely interesting. Sikiric et al. (2018, Current Pharmaceutical Design) demonstrated that BPC-157 reduced intestinal inflammation and accelerated mucosal healing in rat colitis models, including effects on nitric oxide pathways and angiogenesis. Separate rodent work published by Klicek et al. (2012, Journal of Physiology and Pharmacology) showed improvements in colonic anastomosis healing. TB-500, a thymosin beta-4 fragment, shows similar anti-inflammatory signals in animal tissue. The problem is stark: not one randomized controlled trial in humans with IBD has tested BPC-157 or TB-500. Zero. The jump from rat colitis to human Crohn's disease skips entire phases of clinical development that exist precisely because animal results routinely fail to translate. Selank and semax have neurological animal data with no IBD relevance whatsoever.

Where does the social media noise diverge from clinical reality?

Testimonial videos compress complex, multi-year disease trajectories into emotionally compelling three-minute arcs. What gets lost is the confounder problem. IBD is characterized by natural remission and flare cycles. A person who starts a peptide during a flare and films their remission six weeks later has documented correlation, not causation. Crohn's disease has a spontaneous remission rate that varies widely depending on disease phenotype. Simultaneously, most patients in these communities are also adjusting diet, stress levels, sleep, and sometimes conventional medications. The peptide gets the credit. The actual mechanisms get none. There is also a sourcing problem that the videos rarely address. Research-grade BPC-157 used in animal studies is not the same as what arrives in unlabeled vials from grey-market suppliers. Purity data on commercially available peptides is inconsistent, and the FDA has not approved BPC-157 for any indication. Compounded peptides operate in a heavily regulated space for good reason.

What should you actually know?

If you have Crohn's disease or ulcerative colitis and you are watching peptide testimonials, here is what the evidence actually supports right now. Biologics like vedolizumab and ustekinumab have strong Phase III trial data showing 40-50% clinical remission rates in moderate-to-severe Crohn's disease (Feagan et al., 2013, NEJM for vedolizumab). These are not perfect drugs. The side effect profiles are real and the failure rate is real. But they have been tested in thousands of humans. BPC-157 has not. The animal data is hypothesis-generating, not practice-changing. If a gastroenterologist is not part of your care team, that is the first gap to close, not the peptide stack. The IBD research pipeline is genuinely active, with S1P receptor modulators and selective JAK inhibitors adding new options. Waiting for human trial data on peptides is not pessimism. It is basic patient protection.